Targeting immune regulatory checkpoints such as CTLA4 and PD-1/PD-L1 axis is the leading the field of cancer immunotherapy. However, these immunotherapies fail to control cancer in a significant number of patients. To study these number of factors that lead to resistance requires the appropriate set of “tools”.
We have procured a unique Keytruda (anti-PD1) resistance Tumor Infiltrating Lymphocyte (TIL) and matching cell line from a melanoma patient that did not respond to Keytruda therapy. This TIL/tumor combination has been well characterized with T cell markers including known checkpoints and tumor markers. In addition, we have characterized the sub-populations of TIL for immunosuppressive populations.